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Abstract 
 
Aim 
Alcoholic hepatitis (AH) is an acute inflammatory liver condition with high early mortality. Steroids 
have proven short-term survival benefit but non-responders have the worst outcomes. There is a 
clinical need to identify these high-risk individuals at presentation. T cells have been implicated in 
alcoholic hepatitis and steroid responsiveness. We aimed to measure ex vivo T cell cytokine 
expression as a candidate biomarker of outcome in patients with AH. 
 
Methods 
Consecutive patients with AH (bilirubin >80µmol/L and AST:ALT>1.5 in heavy alcohol consumers with 
discriminant function [DF]≥32), were recruited from University Hospitals Plymouth NHS Trust. T cells 
were obtained and stimulated ex vivo before cytokine expression was determined by flow cytometry 
and protein multiplex analysis.  
 
Results  
Twenty-three patients were recruited (10 male; median age 51; baseline DF 67; 30% 90-day 
mortality). Compared to non-survivors at day 90, T cells from survivors had higher baseline 
intracellular IL-10:IL-17A ratio (0.43 v 1.20; p=0.02). Multiplex protein analysis identified IFNγ and 
TNFα as independent predictors of 90-day mortality (p=0.04 and p=0.01 respectively). The ratio of 
IFNγ/TNFα was predictive of 90-day mortality (1.4 v 0.2; p=0.03). 
 
Conclusions 
These data demonstrate the potential utility of T cell cytokine release assays performed on pre-
treatment blood samples as biomarkers of survival in severe AH. Our key findings were that both the 
ratio of intracellular IL-10 to IL-17A and the ratio of IFNγ to TNFα in culture supernatants were 
predictors of 90-day mortality. This offers the promise of developing T cell based diagnostic tools for 
risk stratification. 
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Introduction 
Alcoholic hepatitis (AH) is an acute inflammatory condition, which carries a high mortality of 30% 
within 90 days1. Steroid treatment is the only therapy with proven short-term survival benefit2. 
However, the worst outcomes are in the 30-40% of patients with a poor response to steroid 
treatment3, and there is a pressing need to identify these high-risk individuals at presentation. 
 
T cells have long been implicated in the pathogenesis of AH and we have previously reported that 
suppression of lymphocyte proliferation correlates with clinical outcome following steroid 
treatment4,5. Given the barriers to the development of this radiation-based assay for clinical 
application and the precedent of functional cytokine release assays for other clinical applications6, 
we sought to evaluate T cell cytokine expression as a candidate biomarker of AH mortality. 
 
 
Case report 
Study design 
The study protocol was approved by the UK’s Health Research Authority (reference: 15/LO/1501) 
and all participants provided written informed consent. Consecutive patients with severe AH, 
defined as recent onset jaundice with bilirubin > 80 µmol/L and AST:ALT > 1.5 in heavy alcohol 
consumers (> 60 g or 80 g ethanol / day in females and males respectively) with a discriminant 
function (DF) score ≥ 32, were recruited from University Hospitals Plymouth NHS Trust. Patients 
received standard care including steroid treatment in the absence of active infection, hepatorenal 
syndrome or gastrointestinal haemorrhage. 
 
T cell isolation, stimulation and statistical analysis 
Whole blood samples were taken before steroid treatment was started with CD4+ T cells isolated by 
negative selection (Stemcell Technologies, Cambridge, UK) and cultured for 4 days in supplemented 
4 
 
media with interleukin (IL)-2 (Sigma-Aldrich, Poole, UK) and T cell receptor stimulation (anti-
CD3/CD28 microbeads; Thermo Fisher Scientific, Loughborough, UK). Cells cultured without T cell 
receptor stimulation were included as controls. T cell receptor stimulation with anti-CD3/CD28 
microbeads was selected as a standardized method of T cell activation, which has been optimized for 
use in other conditions7. For the final 4 hours, cultures were stimulated with T cell mitogen phorbol 
12-myristate 13-acetate (PMA) and ionomycin (Sigma) with golgi export inhibitor (BD Biosciences, 
Oxford, UK). Cells were fixed, permeabilised and stained with fluorescently labelled antibodies to IL-
10, IL-17A and interferon gamma (IFNγ) (Thermo Fisher Scientific), quantified on a BD Accuri flow 
cytometer (BD Biosciences) and analysed in FlowJo (FlowJo LLC, Ashland, OR, USA). Protein 
concentration in cell culture supernatants prior to the final 4 hour stimulation was analysed in 
duplicate for CCL20, GM-CSF, IFNγ, IL-10, IL-12p70, IL-17A, IL-21, IL-23, IL-4, IL-6 and TNFα using a 
magnetic bead array (R&D Systems, Minneapolis, MN) on a Luminex 200 analyser (Luminex Corp, 
Austin, TX). Statistical analysis was performed using IBM SPSS version 24 (IBM, Armonk, NY). The 
primary clinical outcome was death within 90 days of presentation. The data presented are median 
values and comparisons were made with non-parametric tests. 
 
Findings 
23 consecutive patients were recruited between April 2016 and November 2017 (10 male; median 
age 51, baseline DF 67, model for end-stage liver disease [MELD] score 19).  90-day mortality was 
30%.  Four patients did not receive steroids because of active infection. Samples were obtained prior 
to steroid treatment in all cases at a median of 5 days from hospital admission. Median time from 
admission to steroid treatment was 6 days. 
 
Compared to non-survivors at day 90, CD4+ T cells from non-survivors had a higher baseline 
intracellular IL-10:IL-17A ratio (percent of T cells expressing IL-10: 2.4% [non-survivors] v 1.6% 
[survivors], p=0.07; IL-17A: 2.1% [non-survivors] v 3.5% [survivors], p=0.08; median IL-10:IL-17A ratio 
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1.20 [non-survivors] v 0.43 [survivors]; p=0.02; figure 1A) with an area under the curve of the 
receiver operating characteristic (AUROC) score of 0.82 (95% confidence interval 0.64-1.00). The 
proportion of T cells expressing IFNγ was similar between groups (14.2% v 11.9%; p=0.55). In 
comparison, expression of cytokines in control cultures was lower than stimulated conditions: IL-10: 
0.2% v 1.8%; IL-17: 2.5% v 3.3%; IFNγ: 6.2% v 13.3% (all p=0.07; Wilcoxon signed ranks test). 
 
Multiplex protein analysis performed on 22 of the 23 cases identified IFNγ and TNFα as most 
differentially expressed between survivors and non-survivors at day 90 (7044 v 2741 pg/ml; p=0.19 
and 2610 v 4098 pg/ml; p=0.08 respectively). Multivariate analysis confirmed that both IFNγ and 
TNFα were independent predictors of 90-day mortality (p=0.04 and p=0.01 respectively). The ratio of 
IFNγ/TNFα was predictive of 90-day mortality (1.4 v 0.2; p=0.03; figure 1B) with an AUROC score of 
0.79 (95% CI 0.58-0.99). The concentration of other mediators tested in the multiplex was similar 
between survivors and non-survivors. No cytokine concentration correlated with baseline DF or 
MELD scores. Steroid response, as determined by Lille score with a threshold of 0.45 at day 7 of 
steroid treatment, was not associated with differences in any cytokine measured by either flow 
cytometry or protein multiplex. Similarly, the ratios of intracellular IL-10/IL-17A and IFNγ/TNFα were 
the same in Lille steroid responders and non-responders. 
 
 
Discussion 
These data from a pilot prospective cohort of more than 20 patients demonstrate the potential 
utility of T cell cytokine release assays performed on pre-treatment blood samples as biomarkers of 
survival in severe AH. Our key findings were that both the ratio of intracellular IL-10 to IL-17A 
measured by flow cytometry in CD4+ cells and the ratio of IFNγ to TNFα in culture supernatants were 
predictors of 90-day mortality. These data also demonstrate that flow cytometry and protein 
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multiplex are complementary techniques that can reveal different alterations in protein expression 
either in proportion of cells secreting a cytokine or in cytokine concentration, respectively.  
 
The pathogenesis of AH is orchestrated by several immune subsets including neutrophils and 
monocytes, which are activated by gut derived signals such as endotoxin8,9. However, T cells also 
play a vital role in responding to antigen presenting cells and propagating inflammation in AH10. 
Transcriptome studies have confirmed upregulation of TNF and T cell pathways 11,12. In particular, 
the Th17 (IL-17 expressing T cell) pathway is upregulated with high expression of related chemokines 
such as CCL2012,13. Furthermore, recent studies have demonstrated that monocytes activated by 
exposure to gut microbial signals interact with CD4+ T cells to alter expression of exhaustion markers 
and cytokines including IFNγ14. These data confirm the relevance of T cells in AH and support the 
measurement of T cell cytokines as a broad measure of immune response.   
 
These findings offer the promise of developing T cell based diagnostic tools for risk stratification 
both in the context of routine clinical practice and also to inform the design of smart clinical trials 
seeking to test new interventions in patients most likely to fail conventional corticosteroid therapy. 
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Figure 1: (A) Ratio of the percentage of CD4+ T cells expressing IL-10:IL-17A measured by flow cytometry (0.4 v 
1.2; p=0.02) and (B) ratio of IFNγ:TNFα concentration measured by protein multiplex in patients with AH alive 
and dead at day 90 (1.4 v 0.2; p=0.03). *p<0.05 
 
